2013-03-04 10:47:06 - New Pharmaceuticals research report from Datamonitor is now available from Fast Market Research
A Complete Response Letter (CRL) describes deficiencies in an NDA/BLA submission that prevent the FDA from approving the application in its original form. Where possible, the CRL will make recommendations for corrective action that the applicant should take. Receipt of a CRL slows approval, causing increased costs and lost sales, and may even prompt withdrawal of the application.
* Assess the impact that an advisory committee vote is likely to have on approval and the probability that a Complete Response Letter will be issued.
* Evaluate how long a Complete Response Letter is likely to delay approval.
Deficiencies in NDA/BLA submissions that triggered a Complete Response Letter include failures of Good Manufacturing Practice, insufficient evidence of clinical efficacy or
safety, clinical data integrity issues, non-clinical studies, and labeling deficiencies. The most common deficiency was insufficient evidence of efficacy or safety.
Full Report Details at
- www.fastmr.com/prod/546442_complete_response_letter_trends_and_a ..
Reasons to Get this Report
* How can applicants reduce the risk that the FDA will issue a Complete Response letter?
* How can company press releases relating to Complete Response Letters provide insight into the likely approval delay?
Report Table of Contents:
Table of Contents
Complete Response Letter Trends and Approval Strategies
Overview of US drug approval regulations and procedures
Complete Response Letters and impact on approval
Take-home messages to avoid Complete Response Letters
Regulations and Procedures of Relevance to Complete Response Letters
The FDA regulatory burden is increasing
US drug submissions process
Complete Response Letters and Impact on Approval
Trends in Complete Response Letters
FDA advisory committee meetings and Complete Response Letters
Take-Home Messages to Avoid Complete Response Letters
Common deficiencies that trigger a Complete Respone Letter
Nucynta ER (tapentadol)
Menveo (meningococcal ACWY vaccine)
Horizant (gabapentin enacarbil)
About the author
The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at www.fastmr.com/catalog/publishers.aspx?pubid=1002
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.